AstraZeneca Stock News

Ähnlich wie Biontech kämpft auch Moderna darum, in einer Post-COVID-19-Welt zurechtzukommen. Neben Forschungserfolgen braucht es Einsparungen.

Biopharmaceutical stock AstraZeneca PLC (NASDAQ:AZN) is 1.3% lower before the open, after a bear note from Deutsche Bank.

TAMPA, Fla.--(BUSINESS WIRE)--Moffitt Cancer Center announces today a strategic collaboration with AstraZeneca that aims to accelerate the development of cell therapies, specifically chimeric antigen receptor T cell (CAR T) and T cell receptor (TCR T) therapies. Under this collaboration, AstraZeneca will have priority access to Moffitt's leading clinical environment and forge strong connections...

Deutsche Bank Research hat Astrazeneca GB0009895292 von "Hold" auf "Sell" abgestuft und das Kursziel von 11000 auf 10500 Pence gesenkt.

AstraZeneca's Dato-DXd showed disappointing overall survival data in the TROPION-Lung01 phase 3 trial. Dato-DXd's progression-free survival benefit, especially in biomarker-positive patients, and the totality of the data, support its potential approval despite underwhelming overall survival results. AstraZeneca has many additional shots on goal with Dato-DXd across first and second line+ lung c...

First patient enrolled in Phase 2a study arm combining BI-1206 with rituximab and acalabrutinibwith initial data expected YE 2024 Clinical supply agreement for acalabrutinib with AstraZeneca in place LUND, SE / ACCESSWIRE / September 12, 2024 /BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class ...

A Phase 3 trial found AstraZeneca's (AZN) experimental lung cancer drug datopotamab deruxtecan (Dato-DXd) did not significantly improve patients' overall survival rates.

The companies commit to bring cutting-edge liquid biopsy testing to 20 institutions globally over the next 12 months BOSTON and ROLLE, Switzerland , Sept. 10, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced a new milestone in the global introduction of the liquid biopsy test MSK-ACCESS...